Media headlines about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 45.8789856675063 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- AMAG Pharmaceuticals, Inc. (AMAG) – Hot Healthcare stock Alert – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Hot Stocks: SPI Energy Co., Ltd., (NASDAQ: SPI), AMAG Pharmaceuticals, Inc., (NASDAQ: AMAG), Essent Group Ltd … – Stocks In The News (press release) (tradingnewsnow.com)
- ETFs with exposure to AMAG Pharmaceuticals, Inc. : December 12, 2017 (finance.yahoo.com)
- AMAG Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of ($6.63) Per Share (AMAG) (americanbankingnews.com)
- Head to Head Analysis: Eli Lilly and (LLY) and AMAG Pharmaceuticals (AMAG) (americanbankingnews.com)
Several research analysts have weighed in on AMAG shares. Jefferies Group reissued a “buy” rating and set a $16.00 price objective on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Wednesday, October 4th. Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Finally, Deutsche Bank reaffirmed a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have assigned a buy rating to the company. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $23.38.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded up $0.07 during midday trading on Wednesday, hitting $14.50. 507,800 shares of the stock traded hands, compared to its average volume of 1,086,879. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $36.83. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://ledgergazette.com/2017/12/13/amag-pharmaceuticals-amag-receives-media-impact-rating-of-0-15.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.